论文部分内容阅读
目的:观察瑞替普酶静脉溶栓治疗急性心肌梗死的梗死相关血管开通率,开通时间及安全性。方法:40例患者均予瑞替普酶静脉溶栓治疗,通过临床间接指标评价开通率并记录不良反应。血管开通时间为从静脉给药结束至ST段回落>50%时间。结果:根据冠脉再通标准判断,40例患病中再通32例(80%)。结论:瑞替普酶适合急性心肌梗死患者的静脉溶栓治疗,可尽快实现闭塞血管的再通,并且安全性较好,值得临床应用。
OBJECTIVE: To observe the infarct-related vascular opening rate, opening time and safety of reteplase in patients with acute myocardial infarction. Methods: Forty patients were treated with reteplase intravenous thrombolytic therapy, and the opening rate was evaluated by indirect clinical indicators and the adverse reactions were recorded. Vascular opening time from the end of intravenous administration to the ST segment down> 50% of the time. Results: According to the standard judgment of recanalization, 32 cases (80%) were recanalized in 40 cases. Conclusion: Reteplase is suitable for intravenous thrombolytic therapy in patients with acute myocardial infarction, as soon as possible to achieve recanalization of occluded vessels, and is safe and worthy of clinical application.